Jefferies Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $28
Jefferies analyst Akash Tewari initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of $28.
Exelixis’s Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
The FDA has approved Exelixis Inc’s (NASDAQ:EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval…
Truist Securities Maintains Buy on Exelixis, Lowers Price Target to $36
Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $37 to $36.
Exelixis Announces U.S. FDA Approval Of CABOMETYX (cabozantinib) For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older
Exelixis’ Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Exelixis Inc (NASDAQ:EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma…
Exelixis – Takeda’s Cabometyx Scores Approval In Japan For Kidney Cancer
Exelixis Inc’s (NASDAQ:EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE:TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The approval…
Exelixis Announces Partner Takeda And Ono Receive Approval In Japan For CABOMETYX In Combination With OPDIVO For The Treatment Of Unresectable Or Metastatic Renal Cell Carcinoma
– Approval based on the phase 3 CheckMate -9ER pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate
Exelixis, Invenra Expand Oncology Pact
Exelixis Inc (NASDAQ:EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented partnership builds…